Key features and details
- Goat polyclonal to Indoleamine 2, 3-dioxygenase
- Suitable for: WB, IHC-P
- Reacts with: Human
- Isotype: IgG
Product nameAnti-Indoleamine 2, 3-dioxygenase antibody
See all Indoleamine 2, 3-dioxygenase primary antibodies
DescriptionGoat polyclonal to Indoleamine 2, 3-dioxygenase
Tested applicationsSuitable for: WB, IHC-Pmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat, Dog
- Human colon tissue.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Storage bufferpH: 7.30
Preservative: 0.02% Sodium azide
Constituents: 99% Tris buffered saline, 0.5% BSA
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab134197 was purified from Goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Our Abpromise guarantee covers the use of ab134197 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 0.5 - 1.5 µg/ml.
A 1 hour primary incubation is recommended for this product. Approx 50kDa band observed in Human Lymph Node, Spleen and Placenta lysates (calculated MW of 45.3kDa according to NP_002155.1).
|IHC-P||Use a concentration of 4 - 6 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionCatalyzes the cleavage of the pyrrol ring of tryptophan and incorporates both atoms of a molecule of oxygen.
PathwayAmino-acid degradation; L-tryptophan degradation via kynurenine pathway; L-kynurenine from L-tryptophan: step 1/2.
Sequence similaritiesBelongs to the indoleamine 2,3-dioxygenase family.
- Information by UniProt
- 3-dioxygenase antibody
- I23O1_HUMAN antibody
- IDO 1 antibody
Immunohistochemical analysis of paraffin-embedded Human colon tissue labelling Indoleamine 2, 3-dioxygenase with ab134197 at 4 µg/ml dilution.
All lanes : Anti-Indoleamine 2, 3-dioxygenase antibody (ab134197) at 0.5 µg/ml
Lane 1 : Human lymph node lysate
Lane 2 : Spleen lysate
Lane 3 : Placenta lysate
Lysates/proteins at 35 µg per lane.
ab134197 has been referenced in 3 publications.
- Mitchell SJ et al. Nicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice. Cell Metab 27:667-676.e4 (2018). PubMed: 29514072
- Zhou CC et al. Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br J Pharmacol 173:2352-68 (2016). PubMed: 27174364
- Strong MJ et al. Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog 9:e1003341 (2013). IHC-P ; Human . PubMed: 23671415